Company profile: ProNova Solutions
1.1 - Company Overview
Company description
- Provider of compact proton therapy systems and project development services for cancer treatment. Offers the ProNova SC360 with pencil beam scanning and cone-beam CT imaging, leveraging superconducting magnet technology in the cyclotron and treatment gantry, and supports design, construction, equipment installation, commissioning, and clinical start-up of proton therapy centers.
Products and services
- Project Development Services: Facility-scale program that architects, constructs, and commissions proton therapy centers, including site development, equipment installation, and clinical start-up support
- ProNova SC360 Proton Therapy System: Compact platform for cancer treatment featuring pencil beam scanning and advanced imaging with cone-beam CT for precise tumor targeting and patient alignment
- Superconducting Magnet Technology: Superconducting magnet technology integrated in the cyclotron and treatment gantry as part of the company’s proton therapy medical system for cancer treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ProNova Solutions
BioMark Diagnostics
HQ: Canada
Website
- Description: Provider of oncology-focused metabolomics-based cancer detection solutions, including a liquid biopsy metabolic panel for early lung cancer diagnosis using urine and plasma, a non-invasive SSAT1 assay leveraging an FDA-approved drug to detect elevated enzyme levels in cancers, a metabolomics-driven detection platform, lung cancer early detection studies, and cancer education videos.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMark Diagnostics company profile →
Flare Therapeutics
HQ: United States
Website
- Description: Provider of precision therapies by targeting transcription factors, including FX-909, a first-in-class small molecule PPARG inhibitor in Phase 1 for advanced solid malignancies such as advanced urothelial carcinoma. Offers a discovery engine and a pipeline of TF-targeted drug programs, with switch site identification, ligandability, and pharmacology capabilities, initially focused on precision oncology and expanding to metabolic, neurology, immunology/inflammation, and rare genetic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flare Therapeutics company profile →
Kairos Pharma
HQ: United States
Website
- Description: Provider of clinical-stage cancer immunotherapies addressing drug resistance: ENV-105 (Endoglin-targeting antibody; Phase I/II for prostate and lung), KROS-201 (activated T cell therapy for glioblastoma), KROS-101 (GITR agonist), KROS-102 (GITR antagonist), KROS-301 (RelA/NF-κB inhibitor), and KROS-401 (IL4/IL13 cyclic peptide for triple-negative breast cancer, with radiation).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kairos Pharma company profile →
Bebig Medical
HQ: Germany
Website
- Description: Provider of distribution services for radiation therapy products, tools, and accessories for cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bebig Medical company profile →
OncoEthix
HQ: Switzerland
Website
- Description: Provider of cancer drug development, advancing a portfolio of three to five promising oncology compounds through clinical development; a private Swiss company founded in 2007.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoEthix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ProNova Solutions
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ProNova Solutions
2.2 - Growth funds investing in similar companies to ProNova Solutions
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ProNova Solutions
4.2 - Public trading comparable groups for ProNova Solutions
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →